Introduction
Langerhans cell histiocytosis (LCH) is a rare disease with a wide variety of clinical presentations, from localized disease to disseminated disease. [1] [2] [3] Although the risk factors for LCH have not been fully elucidated, patients younger than 2 years of age at onset, with risk organ involvement, including the hematopoietic system, liver, spleen, or lung, and disease refractory to conventional chemotherapy have a very poor outcome, with survival rates of about 20%. [4] [5] [6] [7] [8] The treatment strategy for these high-risk LCH patients has not yet been established. Recently, it was reported that a combination of 2-chlorodeoxyadenosine (2-CdA) and cytarabine (Ara-C) was effective for refractory LCH. 9 Allogeneic stem cell transplantation (SCT) has also been used because of its strong immunomodulatory effects for LCH. 10, 11 This report describes the improved outcomes of 15 children with refractory LCH who underwent SCT in Japan.
Patients and methods

Data collection
The HLH/LCH committee of the Japanese Society of Pediatric Hematology (JSPH) sent the first questionnaires to all hospitals in Japan where pediatric hematologists (JSPH members) worked, asking for the number of children with LCH who underwent SCT between November 1995 and March 2007. The second questionnaires were then sent to 16 hospitals where SCT was done for LCH, asking about the clinical features at onset, treatment before SCT, donor source, conditioning regimen, complications, and outcome. Thirteen hospitals responded to the second questionnaires, with a total of 15 eligible patients. The registration data of the pediatric SCT program, independently managed by the SCT committee of the JSPH, were also available to confirm the profiles of the patients who underwent SCT.
Diagnostic criteria and definition of disease state All patients were diagnosed as having LCH by histopathological examination of the affected organs, which were positive for either CD1a or S100 staining. Each patient was divided into one of three subsets at diagnosis: single system single-site (SS-s), single system multi-site (SS-m), and multisystem (MS). In the MS subset, patients with one of the following factors were classified as the high-risk group: younger than 2 years of age at onset; risk organ involvement, including the hematopoietic system (bone marrow, BM), liver, spleen, or lung; or disease refractory to conventional chemotherapy. Patients without these factors in the MS, SSm, and SS-s subsets were classified as the low-risk group. The characteristics of these 15 patients are shown in Table 1 . The disease state was evaluated at three time-points in all patients: (1) within 6 weeks after initial diagnosis, (2) within 12 or 14 weeks after diagnosis, and (3) before SCT. A good response (GR) was defined as the disappearance of signs or symptoms of disease; a partial response (PR) was defined as regression 450% of signs or symptoms of disease with no organ dysfunction and no new lesions; a non-response (NR) was defined as regression o50% of signs or symptoms of disease with or without organ dysfunction and no new lesions; and progressive disease (PD) was defined as progressive signs or symptoms of disease and/or the appearance of new lesions. 8 
Statistical analyses
Continuous variables were compared using the MannWhitney U-test. The overall survival (OS) rate with standard error (s.e.) was estimated using the Kaplan-Meier method and compared using the log-rank test. 12 The OS was calculated for the period from the day of diagnosis until the day of death from any cause. The outcome data were updated in December 2008.
Results
Clinical course of 15 patients before SCT Between November 1995 and March 2007, 15 children (9 males, 6 females) with LCH refractory to conventional chemotherapy underwent SCT at 13 institutions. The characteristics of all 15 patients are summarized in Table 1 , and the details of each patient are shown in Table 2 . The median age at diagnosis was 8 months (range, 28 days to 28 months). At initial diagnosis, 12 patients had MS type LCH, and nine had risk organ involvement, including the liver (n ¼ 6), spleen (n ¼ 5), lung (n ¼ 5), and/or hematopoietic system (n ¼ 4). One patient had diabetes insipidus (DI) and pituitary gland involvement at diagnosis. No CNS disorders other than DI were found in any of the patients. Two patients had SS-m type LCH at diagnosis, with multiple bone lesions. One patient had SS-s type LCH, with thymus involvement and respiratory dysfunction at initial diagnosis.
Eleven patients had received conventional chemotherapy according to the study protocol JLSG-96 (n ¼ 4) or JLSG-02 (n ¼ 4) of the Japan LCH study group, 8 and DAL-HX 83 (n ¼ 3) of the Deutsche Arbeitsgemeinschaft fur Leukaemieforschung Histiocytosis X-83 study group. 4 Remaining four patients had received multi-drug chemotherapy following their institutional protocol. Two patients received the combination of 2-CdA and high dose Ara-C before SCT as salvage therapy and failed to achieve complete remission (patients 6 and 8). Six weeks after initial diagnosis, the disease state was PD (n ¼ 6), NR (n ¼ 2), PR (n ¼ 5), and GR (n ¼ 2). Twelve or 14 weeks after chemotherapy, the disease state was PD (n ¼ 6), NR (n ¼ 0), PR (n ¼ 6), and GR (n ¼ 3). Eleven patients with MS type, two with SS-m type, and one with SSs type at diagnosis had risk organ involvement before SCT.
The median age at SCT of 15 patients was 23 months (range, 13-178 months). At SCT, 14 patients had risk organ involvement. The affected organs before SCT were liver (n ¼ 10), hematopoietic system (n ¼ 7), and lung (n ¼ 4). Five of six patients in the low-risk group had risk organ involvement at SCT.
The disease status of six patients (patients 2-6 and patient 8) in the high-risk group was PD with risk organ involvement at SCT. The disease status of patient 2 was PD despite chemotherapy according to the JLSG-02 protocol, and liver dysfunction developed gradually. BM involvement was observed in patients 3-6, patient 8, patient 9, and patient 13 despite multi-drug chemotherapy. Patient 3, patient 6, and patient 8 suffered from serious infections before SCT. All six of these patients underwent SCT during 8-11 months after diagnosis. The disease status of the other three patients (patient 1, patient 7, and patient 9) was PR or NR with risk organ involvement at SCT. These three patients underwent SCT for 12-30 months after diagnosis.
Three of the six patients in the low-risk group (patient 10, patient 12 and patient 14) had suffered from recurrent active disease for 6, 13, and 7 years, respectively, despite chemotherapy consisting of vincristine, pirarubicin, prednisone, Ara-C, vinblastine, etoposide, and cyclophosphamide with or without cyclosporine. At recurrence, lung involvement and left phrenic nerve palsy were observed in patient 10, who required oxygen for 2 months. Patient 12 had recurrence of multiple bone lesions, including the ear, and needed a hearing aid. She relapsed twice with multiple SCT for LCH in Japan K Kudo et al skull lesions and occurrence of DI, despite chemotherapy. Patient 14 developed systemic xanthogranuloma 3 years after diagnosis. He suffered from liver dysfunction, ascites, pleural effusion, fever, and pancytopenia before SCT. Among the remaining three patients, patient 13, who relapsed during maintenance therapy, became refractory to more intensive chemotherapy, and BM and CNS involvement occurred at SCT. Patient 11 suffered from diarrhea, bloody stool, and protein-losing gastroenteropathy at initial diagnosis. After 2 months, skin rash, hepatosplenomegaly, and disseminated intravascular coagulation were seen and she was diagnosed based on a rectal biopsy. She failed to achieve remission after JLSG Induction regimen A and B and received cisplatin according to the neuroblastoma regimen after disease activation. Patient 15 failed to achieve remission after the JLSG Induction regimen and received chemotherapy according to the non-Hodgkin lymphoma regimen. Patient 15, who had thymus involvement and respiratory dysfunction at diagnosis, obtained only a PR clinically and radiographically, and the skin, lung, gingiva, and palpebral conjunctiva became involved 6 months after diagnosis.
Donor source and conditioning regimen
The donor source and conditioning regimen for SCT are also summarized in Table 2 . A myeloablative conditioning regimen was used in 10 patients; total body irradiation was used in five, while the other five received a non-total body irradiation regimen. Five patients received a reducedintensity conditioning regimen (RIC), which consisted of fludarabine, melphalan, or cyclophosphamide, and lowdose total body irradiation/total lymph node irradiation and/or antithymocyte globulin. Nine patients underwent unrelated cord blood transplantation. One patient received cord blood from an HLA-matched sibling. Overall, 10 of 15 patients received CBT with a median of 1.4 Â 10 
Clinical course of 15 patients after SCT
The clinical course of 15 patients after SCT is listed in Table 2 . Engraftment with 4500/ml absolute neutrophil count was seen in all patients except for one who died of multi-organ failure on day 18. Regimen-related toxicity was seen in six of 15 patients; mucositis of grade 1 to grade 4 according to the common terminology criteria for adverse events 13 was the most common, and three patients had liver dysfunction of grade 2 or grade 3. One patient had thrombotic microangiopathy, which resolved without long-term sequelae. Four patients had various infections, such as sepsis, herpes simplex virus, and cytomegalovirus. Three patients who underwent unrelated cord blood transplantation had acute graft-versus-host disease (grades I, III, IV). One of them and another patient developed chronic graft-versus-host disease extensive type.
After SCT, two patients never entered remission and died on day 18 and day 188, respectively (patient 2 and patient 8). Patient 7 relapsed on day 20 and died on day 47 after SCT, due to sepsis, veno-occlusive disease, and gastrointestinal bleeding. Patient 4 underwent a second SCT on day 49 after the first SCT because of graft failure. She relapsed on day 194 and died on day 271 after the second SCT due to liver dysfunction, pancytopenia, and sepsis. Two patients (patient 10 and patient 12) relapsed at 8 months and 4 months after auto-PBSCT, respectively. Patient 10 had recurrence involving the cervical spine and received prednisone, vinblastine, and cyclosporine for 4 years. Patient 12 had recurrence of multiple bone lesions, including the femur, skull, and scapula in turn, and was treated with radiation therapy to control the bone lesions for 2 years. Patient 14 had macrophage activating syndrome after SCT, and TNF-a blocker and dexamethasone palmitate were administered for several months. Finally, 11 of 15 patients remain alive with no evidence of disease. The 10-year OS rate (median±s.e.) in these patients was 73.3 ± 11.4% (Figure 1 ). The 10-year OS rate of nine patients who had risk organ involvement at diagnosis was 55.6±16.6%, whereas six patients who had no risk organ involvement at diagnosis have all survived with no evidence of disease. There was no significant difference in outcome between the two groups (P ¼ 0.07), because of the small number of patients.
Late toxicities associated with SCT included short stature with body height oÀ2.0 s.d. in five patients, whereas DI and hearing disturbance were seen in two patients each. One patient, who had a hip fracture and hearing disturbance, was evaluated as being intellectually retarded. Another patient, who suffered from a CNS lesion before SCT, had speech delay. Except for one infant who was too young to evaluate, the Karnofsky score 14 of the remaining eight survivors was 100%. SCT. The 10-year OS rate of the 15 patients with refractory LCH who underwent SCT was 73.3±11.4%. The 10-year OS rate of the nine patients who had risk organ involvement at diagnosis was 55.6±16.6%, whereas all six patients who had no risk organ involvement at diagnosis remain alive with no evidence of disease. There was no significant difference in outcome between the two groups (P ¼ 0.07). RO, risk organ.
Discussion
More than 40 patients with refractory LCH have been reported to have received SCT since 1987. 15 The OS of the 29 patients who underwent myeloablative SCT was 48% (14/29 patients), and the transplant-related mortality was 45%. However, in a recent study reported from Europe, 10 seven (78%) of nine patients survived with no signs of disease activity after RIC-SCT. The conditioning regimen consisted of fludarabine, melphalan, low-dose total lymph node irradiation (2 Gy), and either of antithymocyte globulin or MabCampath (anti-CD52 antibody). In Japan, four patients with LCH underwent SCT between 1994 and 1997, and two of them (50%) survived. 16 In this study, 11 of the 15 patients have survived with no evidence of disease; 8/ 10 (80%) with myeloablative conditioning and 3/5 (60%) with RIC-SCT, and the 10-year OS rate was superior (73.3 ± 11.4%). In particular, two patients with RIC-SCT had organ dysfunction before SCT, suggesting that a less toxic conditioning regimen is also effective for patients with organ dysfunction.
In the recent report of 22 patients who underwent SCT, the donor source was a sibling in 17 (77%) and a matched unrelated donor in five (23%). 11 The stem cell source was BM in 12 (55%), PB in six (27%), and CB in four (18%).
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In this study, 10 of 15 patients received UCB, and eight of these have survived with no evidence of disease, including three with RIC-SCT. Therefore, our results support the use of UCB as an alternative donor source when neither a sibling donor nor a matched unrelated donor is available.
The appropriate timing of SCT for LCH is unclear. In this study, nine of 15 patients underwent SCT within 12 months after initial diagnosis, including seven with risk organ involvement at diagnosis. This group had a lifethreatening clinical course, and they required prompt SCT as the only potentially curative treatment. On the other hand, three patients without risk organ involvement at initial diagnosis underwent SCT 7 years or later after diagnosis, resulting in no evidence of disease. A total of six patients in the low-risk group underwent SCT because of PD or disease refractory to conventional chemotherapy. Although it is not known which LCH patients really require SCT, our findings suggest that SCT should also be considered in patients in the low-risk group at diagnosis who develop active or PD even after long-term chemotherapy. A large-scale prospective study could provide useful information to select subsets of LCH that definitely need SCT.
It has recently been shown that various cytokines have an important role in the pathogenesis of LCH, suggesting that eradication of the pathologic cells associated with cytokine production could be effective for refractory LCH. In the previous report, two patients with refractory LCH who underwent RIC-SCT showed resolution of disease after SCT. 10 Kinugawa et al. 16 reported one patient who failed engraftment, followed by complete autologous recovery and resolution of disease activity. 16 In this study, one patient who underwent allo-BMT (patient 9) had a similar clinical course. Two patients who relapsed after auto-PBSCT showed resolution of disease following conventional chemotherapy (patients 10 and 12). Although the disease state of the two patients at 12 or 14 weeks after chemotherapy was GR, multiple recurrences had occurred, and their disease state at SCT was PD. These two patients were rescued by a myeloablative conditioning regimen with infusion of donor T lymphocytes, which prevented deterioration of the LCH. Steiner et al. 17 also reported one patient who achieved complete remission after RIC-SCT, despite post transplant mixed chimerism, in which only a T-cell subset proved to be of donor origin. He emphasized that a strong immunomodulating influence, mainly exerted by allogeneic T-cells, rather than eradication of the LCH cell clone, may be potentially curative in LCH. Correction of inappropriate immunological crosstalk by the replacement of allogeneic donor cells may be pivotal.
Bernard et al. 9 reported that 7 of 10 patients with refractory LCH had achieved sustained complete remission after treatment with 2-CdA and Ara-C. In this study, two patients (patients 6 and 8), who failed to respond to the combination of 2-CdA and Ara-C, underwent SCT, and one has been alive with no disease after RIC-SCT. Prior utilization of 2-CdA may help tailor the indications for SCT.
In conclusion, the improved outcomes of SCT for refractory LCH show that it is a promising new salvage approach. RIC-SCT is desirable for young children, especially with non-malignant disease. Further investigations are required to establish the SCT strategy for refractory LCH.
